VCU Massey Cancer Center at Stony Point

Summary

VCU Massey Cancer Center at Stony Point is a medical facility located in Richmond, Virginia. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Colorectal Cancer and other specialties. VCU Massey Cancer Center at Stony Point is involved with conducting 183 clinical trials across 210 conditions. There are 30 research doctors associated with this hospital, such as Andrew Poklepovic, MD, Sarah W. Gordon, DO, Leslie Randall, MD, and Erin R. Alesi.

Top PIs

Clinical Trials running at VCU Massey Cancer Center at Stony Point

Prostate Cancer

Breast Cancer

Lung Cancer

Cancer

Bladder Cancer

Laryngeal Cancer

Oropharyngeal Carcinoma

Breast cancer

Throat Cancer

Esophageal cancer

Carboplatin + Cabazitaxel

for Prostate Cancer

This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels (castrate-resistant) and that has spread from where it first started (primary site) to other places in the body (metastatic). Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Chemotherapy drugs, such as cabazitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Prednisone is often given together with chemotherapy drugs. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs and to help the chemotherapy work. Giving carboplatin with the standard of care chemotherapy drug cabazitaxel may be better at treating metastatic castrate-resistant prostate cancer.

Recruiting

2 awards

Phase 3

5 criteria

Shorter vs Usual Radiation Therapy

for Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation prevents cancer from coming back as well as the usual radiation treatment.

Recruiting

2 awards

Phase 3

10 criteria

Standard Therapy + Surgery/Radiation

for Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.

Recruiting

2 awards

Phase 3

30 criteria